Every material Form 8-K CERENOME, INC. has filed with the SEC since August 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 30, 2026, Cerenome updated its corporate presentation for meetings with investors and analysts, and filed the updated slides as Exhibit 99.1 to a Form 8-K dated October 2, 2026. The filing contains no financial statements or guidance, so it gives shareholders operating metrics and milestone timelines rather than new financial results.
Filed under Item 8.01 (Other Events); presentation dated September 30, 2026 is Exhibit 99.1.
Presentation cites 24 commercial ordering institutions and 187 commercial CNSide TCE specimens in Q3 2026 through September 30, 2026, presented as actuals.
Medicare rate for CNSide expected effective January 1, 2027; Molecular Profile test launch planned for October 12, 2026.
The filing includes no financial statements or guidance; the presentation's forward-looking statements carry stated risks.
On September 4, 2026, Cerenome entered into a securities purchase agreement with an institutional investor for senior secured convertible notes with an aggregate original principal of $21,276,596, with an initial closing expected on or about September 10, 2026. The notes are secured by substantially all company and CNSide assets, carry 8.0% interest and a one-year maturity, and convert into common stock, and a royalty of 2.5% of CNSide gross revenues is expected to be paid to the investor, so the financing adds secured debt, a revenue-linked payment and potential share dilution for shareholders.
Aggregate original principal of $21,276,596, including $3,191,489 Initial Notes, $2,127,660 Second Notes and $15,957,447 Additional Notes.
Expected gross proceeds of $3,000,000 at the initial closing on or about September 10, 2026, before legal fees and transaction expenses.
Notes carry 8.0% interest and a 6.0% original issue discount, mature one year after issuance, and have an initial conversion price of $2.74 per share with a $0.50 floor.
Quarterly royalty of 2.5% of CNSide gross revenues, guaranteed by Cerenome, remains in effect until the notes are paid in full.
Cerenome reported second quarter 2026 results on August 14, 2026. Grant revenue fell to $0.4 million from $1.4 million a year earlier, the operating loss widened to $9.1 million from $1.5 million, and the company posted a net loss of $9.0 million, or $1.31 per basic share, compared with net income of $5.2 million in the prior-year quarter, which included a $6.5 million gain from a change in fair value of derivative instruments. Cash and investments totaled $8.6 million at June 30, 2026, and the company affirmed its 2026 milestones and outlook without changes.
Operating loss was $9.1 million in Q2 2026 versus $1.5 million in Q2 2025, which the company attributes mainly to expansion of CNSide commercial operations and funding of the REYOBIQ Phase 2 trial.
Net loss was $9.0 million, or $1.31 per basic share, versus net income of $5.2 million, or $0.62 per basic share, in Q2 2025.
Cash, cash equivalents and investments were $8.6 million as of June 30, 2026.
The company affirmed its 2026 milestones, including ReSPECT-GBM data expected in Q1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CERENOME, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →